MiNK Therapeutics INKT
NASDAQ INKT
$10.06 -0.56 (-5.27%)
At close: Oct 22, 2026 · 4:00 PM EDT

MiNK Therapeutics (INKT) Convertible Debt (2020)

Updated

MiNK Therapeutics (INKT) posted Convertible Debt of $43.82 million for Q4 2020.

Analysis

MiNK Therapeutics (INKT) Convertible Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 MiNK Therapeutics 51.27 Mn 10.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 43.82 Mn
API Access

MiNK Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=INKT&period=max&api_key=YOUR_API_KEY